ACLX: Arcellx Inc. Stocks News on September 12, 2025

Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius

ACLX

BioPharma Dive

22 days ago

Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius

EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma

ACLX

Clinical Trials Arena

3 months ago

EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma

ACLX

MT Newswires

3 months ago

Citigroup Initiates Arcellx at Buy With $110 Price Target

Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

ACLX

Business Wire

4 months ago

Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

ACLX

Insider Monkey

4 months ago

Baron Discovery Fund Initiated a Position in Arcellx (ACLX)

ACLX

MT Newswires

4 months ago

Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise

$Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma$

ACLX

Business Wire

4 months ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

ACLX

Insider Monkey

4 months ago

Here’s Why Arcellx (ACLX) Declined in Q1

Arcellx First Quarter 2025 Earnings: Misses Expectations

ACLX

Simply Wall St.

4 months ago

Arcellx First Quarter 2025 Earnings: Misses Expectations

ACLX

Zacks

4 months ago

Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

ACLX

Business Wire

4 months ago

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

ACLX

Insider Monkey

5 months ago

Arcellx, Inc. (ACLX): Among Takeover Rumors Hedge Funds Are Buying

ACLX

Insider Monkey

5 months ago

Arcellx (ACLX): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

ACLX

Business Wire

6 months ago

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

ACLX

Simply Wall St.

6 months ago

We're Not Worried About Arcellx's (NASDAQ:ACLX) Cash Burn

ACLX

Zacks

7 months ago

Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

ACLX

Business Wire

7 months ago

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

ACLX

MT Newswires

7 months ago

Arcellx Insider Sold Shares Worth $2,375,517, According to a Recent SEC Filing

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

ACLX

Business Wire

7 months ago

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

ACLX

Insider Monkey

7 months ago

Is Arcellx, Inc. (ACLX) An Oversold Biotech Stock to Buy Now?

ACLX

Insider Monkey

7 months ago

Is Arcellx (ACLX) Poised to Capture Significant Market Share?

Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?

ACLX

Zacks

8 months ago

Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?

ACLX

Argus Research

8 months ago

Daily – Vickers Top Buyers & Sellers for 01/13/2025

ACLX

MT Newswires

8 months ago

Arcellx Insider Sold Shares Worth $2,263,942, According to a Recent SEC Filing

ACLX

MT Newswires

8 months ago

Arcellx Insider Sold Shares Worth $1,355,024, According to a Recent SEC Filing

Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock?

ACLX

Zacks

8 months ago

Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock?

ACLX

MT Newswires

8 months ago

Arcellx Insider Sold Shares Worth $2,244,896, According to a Recent SEC Filing

Arcellx Stock Earns 82 Relative Strength Rating

ACLX

Investor's Business Daily

9 months ago

Arcellx Stock Earns 82 Relative Strength Rating

ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma

ACLX

Clinical Trials Arena

9 months ago

ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma

ACLX

MT Newswires

9 months ago

Gilead Sciences, Arcellx's CAR-T Therapy Supports 2030 Oncology Ambitions, Oppenheimer Says

ACLX

MT Newswires

9 months ago

UBS Raises Price Target on Arcellx to $114 From $106, Maintains Buy Rating

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

ACLX

Investor's Business Daily

9 months ago

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

ACLX

MT Newswires

9 months ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday

ACLX

MT Newswires

9 months ago

Sector Update: Health Care

ACLX

Benzinga

9 months ago

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

ACLX

MT Newswires

9 months ago

Arcellx Says Trial of Multiple Myeloma Drug Candidate Achieves 97% Overall Response Rate

$Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition$

ACLX

Business Wire

9 months ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

ACLX

Zacks

10 months ago

Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice

ACLX

MT Newswires

10 months ago

Arcellx Insider Sold Shares Worth $1,242,170, According to a Recent SEC Filing

Arcellx Third Quarter 2024 Earnings: Misses Expectations

ACLX

Simply Wall St.

10 months ago

Arcellx Third Quarter 2024 Earnings: Misses Expectations

ACLX

Zacks

10 months ago

Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?

ACLX

Zacks

10 months ago

Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

ACLX

Business Wire

10 months ago

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Arcellx price target raised to $106 from $81 at Morgan Stanley

ACLX

TipRanks

10 months ago

Arcellx price target raised to $106 from $81 at Morgan Stanley

ACLX

Zacks

10 months ago

Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?

ACLX

MT Newswires

10 months ago

Morgan Stanley Adjusts Arcellx's Price Target to $106 From $81, Keeps Overweight Rating

$Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study$